J
Jeff Evans
Researcher at Beatson West of Scotland Cancer Centre
Publications - 33
Citations - 1764
Jeff Evans is an academic researcher from Beatson West of Scotland Cancer Centre. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 10, co-authored 26 publications receiving 1230 citations. Previous affiliations of Jeff Evans include Western Infirmary & University of Glasgow.
Papers
More filters
Journal ArticleDOI
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
John N. Primrose,Richard Fox,Daniel H. Palmer,Hassan Malik,Raj Prasad,Darius F. Mirza,Alan Anthony,Pippa Corrie,Stephen Falk,Meg Finch-Jones,Harpreet Wasan,Paul Ross,Lucy Wall,Jonathan Wadsley,Jeff Evans,Deborah D. Stocken,Raaj K. Praseedom,Yuk Ting Ma,Brian R. Davidson,John P. Neoptolemos,Timothy Iveson,James Raftery,Shihua Zhu,David Cunningham,O. James Garden,Clive Stubbs,Juan W. Valle,John Bridgewater +27 more
TL;DR: This randomised, controlled, multicentre, phase 3 study aimed to determine whether adjuvant capecitabine improved overall survival compared with observation following surgery for biliary tract cancer.
Journal ArticleDOI
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer,Chris Jones,Mark R. Middleton,Richard H. Wilson,Jeff Evans,Anna L. Olsen,Nicola J. Curtin,Alan V. Boddy,Peter J. McHugh,David R. Newell,Adrian L. Harris,Patrick Johnson,Heidi Steinfeldt,R. Dewji,Diane Wang,L Robson,Hilary Calvert +16 more
TL;DR: The combination of AG014699 and temozolomide is well tolerated, pharmacodynamic assessments showing proof of principle of the mode of action of this new class of agents is shown.
Journal ArticleDOI
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton,Paul Silcocks,Trevor Cox,Juan W. Valle,Jonathan Wadsley,David Propper,Fareeda Y. Coxon,Paul Ross,Srinivasan Madhusudan,Tom Roques,David Cunningham,Stephen Falk,Nick Wadd,Mark Harrison,Pippa Corrie,Timothy Iveson,A. Robinson,Karen McAdam,Martin Eatock,Jeff Evans,Caroline Archer,Tamas Hickish,Angel Garcia-Alonso,Marianne Nicolson,W.P. Steward,Alan Anthoney,William Greenhalf,Victoria Shaw,Eithne Costello,Dean J. Naisbitt,Charlotte L. Rawcliffe,Gemma Nanson,John P. Neoptolemos +32 more
TL;DR: Adding GV1001 vaccination to chemotherapy did not improve overall survival and new strategies to enhance the immune response effect of telomerase vaccination were not found.
Journal ArticleDOI
A framework for the development of effective anti-metastatic agents.
Robin L. Anderson,Robin L. Anderson,Theo Balasas,Juliana Callaghan,R. Charles Coombes,Jeff Evans,Jacqueline A. Hall,Sally A. Kinrade,David Jones,Paul S. Jones,Robert Jones,John Marshall,Maria Beatrice Panico,Jacqui Shaw,Patricia S. Steeg,Mark T. Sullivan,Warwick Tong,Andrew D. Westwell,James W. A. Ritchie +18 more
TL;DR: The challenges associated with discovering and developing anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer are described and guidance on how these challenges might be overcome is provided.
Journal ArticleDOI
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Julien Edeline,Jean-Frédéric Blanc,Philip J. Johnson,Philip J. Johnson,Boris Campillo-Gimenez,Paul Ross,Yuk Ting Ma,Yuk Ting Ma,Judy King,Richard A Hubner,K Sumpter,Suzanne Darby,Jeff Evans,Chinenye Iwuji,Daniel Swinson,Peter Collins,Kinnari Patel,Iqtedar Muazzam,Daniel H. Palmer,Daniel H. Palmer,Tim Meyer +20 more
TL;DR: The Albumin‐Bilirubin (ALBI) grade was proposed as an objective means to evaluate liver function in patients with Hepatocellular Carcinoma (HCC) but comparison with the subclassification by points (5–15) within the CP classification is not provided.